Drug Trial Radar · NCT07088159
Intermediate-size Patient Population Expanded Access Protocol
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- SpinogenixIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years, up to 85 years
Summary
As written by the sponsor on the registry.
The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.
Conditions
- ALS (Amyotrophic Lateral Sclerosis)
Interventions
TazbentetolDrug
300 mg Tazbentetol will taken by mouth once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama · Available
Mayo Scottsdale
Scottsdale, Arizona · Available
Kaiser Permanente Los Angeles
Los Angeles, California · Available
Cedar-Sinai Medical Center
Los Angeles, California · Available
California Pacific Medical Center
San Francisco, California · Available
Nova Southeastern University
Davie, Florida · Available
Synapticure
Chicago, Illinois · Available
University of Kansas Medical Center
Kansas City, Kansas · Available
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire · Available
Atlantic Health
Summit, New Jersey · Available
New Mexico VA Health Care System
Albuquerque, New Mexico · Available
NYU Langone Health
New York, New York · Available
Columbia University Medical Center
New York, New York · Available
Thomas Jefferson University
Philadelphia, Pennsylvania · Available
Baylor College of Medicine
Houston, Texas · Available
VCU ALS Research Group
Henrico, Virginia · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.